Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 16/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 16/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 16/20 | 0.48 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17678028 | 0.82 | GABRG2 (0.50) | GABRG2GABRB3GABRA5GRIN2BMEN1 | |
| SCHEMBL23507976 | 0.81 | NPC1 (0.55) | MAP3K14MEN1KMT2ANPC1GAA | |
| SCHEMBL17678092 | 0.79 | GABRG2 (0.50) | GABRG2GABRB3GABRA5GRIN2B | |
| SCHEMBL19697969 | 0.78 | GABRG2 (0.47) | GABRG2GABRB3GABRA5GRIN2BMEN1 | |
| SCHEMBL12938768 | 0.78 | GABRG2 (0.47) | GABRG2GABRB3GABRA5GRIN2BMEN1 | |
| SCHEMBL19703607 | 0.78 | GABRG2 (0.44) | GABRG2GABRB3GABRA5GRIN2BMEN1 | |
| SCHEMBL4249780 | 0.75 | GABRG2 (0.47) | GABRG2GABRB3GABRA5 | |
| SCHEMBL12767960 | 0.75 | NPSR1 (0.49) | GABRG2GABRB3GABRA5GRIN2BMEN1 | |
| SCHEMBL16404602 | 0.74 | HTT (0.62) | GABRG2GABRB3GABRA5 | |
| SCHEMBL13596772 | 0.73 | POLB (0.44) | MAP3K14GRIN2BMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | GABRG2 2674/4885GABRB3 2989/4885GABRA5 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.